Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1

The most common type of kidney cancer in adults is renal cell carcinoma (RCC), which accounts for approximately 90% of cases. RCC is a variant disease with numerous subtypes; the most common subtype is clear cell RCC (ccRCC, 75%), followed by papillary RCC (pRCC, 10%) and chromophobe RCC (chRCC, 5%). To identify a genetic target for all subtypes, we analyzed The Cancer Genome Atlas (TCGA) databases of ccRCC, pRCC, and chromophobe RCC. Enhancer of zeste homolog 2 (EZH2), which encodes a methyltransferase, was observed to be significantly upregulated in tumors. The EZH2 inhibitor tazemetostat induced anticancer effects in RCC cells. TCGA analysis revealed that large tumor suppressor kinase 1 (LATS1), a key tumor suppressor of the Hippo pathway, was significantly downregulated in tumors; the expression of LATS1 was increased by tazemetostat. Through additional experiments, we confirmed that LATS1 plays a crucial role in EZH2 inhibition and has a negative association with EZH2. Therefore, we suggest that epigenetic control could be a novel therapeutic strategy for three subtypes of RCC.

[1]  S. Zhuang,et al.  Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases , 2021, Frontiers in Physiology.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  K. Maedler,et al.  Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism , 2018, Trends in Endocrinology & Metabolism.

[4]  R. Uzzo,et al.  Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies , 2018, Molecular Cancer Therapeutics.

[5]  W. Béguelin,et al.  Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.

[6]  J. Bai,et al.  EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis , 2018, Journal of experimental & clinical cancer research : CR.

[7]  Peter C. Hollenhorst,et al.  EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. , 2017, Cancer research.

[8]  S. Welford,et al.  HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism , 2017, Nature Communications.

[9]  Lisa C. Wallace,et al.  Targeting Glioma Stem Cells through Combined BMI1 and EZH2 Inhibition , 2017, Nature Medicine.

[10]  J. Minna,et al.  Developing EZH2-Targeted Therapy for Lung Cancer. , 2016, Cancer discovery.

[11]  R. Margueron,et al.  Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors , 2016, Cell cycle.

[12]  S. Zhuang,et al.  Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. , 2016, Journal of the American Society of Nephrology : JASN.

[13]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[14]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[15]  Hongqing Zhao,et al.  Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis , 2016, Scientific Reports.

[16]  Kun-Liang Guan,et al.  Mechanisms of Hippo pathway regulation , 2016, Genes & development.

[17]  S. Bicciato,et al.  Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.

[18]  K. Guan,et al.  Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.

[19]  Randy L. Johnson,et al.  AMPK modulates Hippo pathway activity to regulate energy homeostasis , 2015, Nature Cell Biology.

[20]  J. Asara,et al.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.

[21]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[22]  M. Hung,et al.  Regulation and Role of EZH2 in Cancer , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  K. Guan,et al.  The Hippo signaling pathway in stem cell biology and cancer , 2014, EMBO reports.

[24]  C. Morais.  Sunitinib resistance in renal cell carcinoma , 2014, Journal of kidney cancer and VHL.

[25]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[26]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[27]  H. Moch.  An overview of renal cell cancer: pathology and genetics. , 2013, Seminars in cancer biology.

[28]  Claudio R. Santos,et al.  Lipid metabolism in cancer , 2012, The FEBS journal.

[29]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[30]  R. Mehra,et al.  Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. , 2012, Cancer research.

[31]  Lothar Hennighausen,et al.  EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer , 2011, International journal of biological sciences.

[32]  S. Goldberg,et al.  Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling , 2010, Molecular Cancer Therapeutics.

[33]  Mala Sinha,et al.  Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma , 2010, PloS one.

[34]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[35]  T. Roskams,et al.  Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. , 2006, Annals of Oncology.

[36]  N. Palavan-Unsal,et al.  Increased Expression of EZH2, a Polycomb Group Protein, in Bladder Carcinoma , 2005, Urologia Internationalis.

[37]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[38]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.